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Background: Dynamic contrast enhanced (DCE) cardiovascular magnetic resonance (CMR) is increasingly used to
quantify microvessels and permeability in atherosclerosis. Accurate quantification depends on reliable sampling of
both vessel wall (VW) uptake and contrast agent dynamic in the blood plasma (the so called arterial input function,
AIF). This poses specific challenges in terms of spatial/temporal resolution and matched dynamic MR signal range,
which are suboptimal in current vascular DCE-CMR protocols. In this study we describe a novel dual-imaging
approach, which allows acquiring simultaneously AIF and VW images using different spatial/temporal resolution and
optimizes imaging parameters for the two compartments. We refer to this new acquisition as SHILO, Simultaneous
HI-/LOw-temporal (low-/hi-spatial) resolution DCE-imaging.
Methods: In SHILO, the acquisition of low spatial resolution single-shot AIF images is interleaved with segments of
higher spatial resolution images of the VW. This allows sampling the AIF and VW with different spatial/temporal
resolution and acquisition parameters, at independent spatial locations. We show the adequacy of this temporal
sampling scheme by using numerical simulations. Following, we validate the MR signal of SHILO against a standard
2D spoiled gradient recalled echo (SPGR) acquisition with in vitro and in vivo experiments. Finally, we show
feasibility of using SHILO imaging in subjects with carotid atherosclerosis.
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Results: Our simulations confirmed the superiority of the SHILO temporal sampling scheme over conventional
strategies that sample AIF and tissue curves at the same time resolution. Both the median relative errors and
standard deviation of absolute parameter values were lower for the SHILO than for conventional sampling schemes.
We showed equivalency of the SHILO signal and conventional 2D SPGR imaging, using both in vitro phantom
experiments (R2 =0.99) and in vivo acquisitions (R2 =0.95). Finally, we showed feasibility of using the newly
developed SHILO sequence to acquire DCE-CMR data in subjects with carotid atherosclerosis to calculate plaque
perfusion indices.
Conclusions: We successfully demonstrate the feasibility of using the newly developed SHILO dual-imaging
technique for simultaneous AIF and VW imaging in DCE-CMR of atherosclerosis. Our initial results are promising and
warrant further investigation of this technique in wider studies measuring kinetic parameters of plaque
neovascularization with validation against gold standard techniques.
Keywords: Atherosclerosis, Neovascularization, Perfusion/permeabilityBackground
Inflammation accompanied by the proliferation of
adventitial microvessels and intra-plaque neovessels is
an important hallmark of vulnerable atherosclerotic
plaques, at high risk of causing severe clinical events [1].
Dynamic Contrast Enhanced (DCE) CMR is a well-
established non-invasive method used to quantify the ex-
tent and properties of tissue microvasculature [2-4]. In
recent years DCE-CMR has been applied to quantify
neovascularization in atherosclerosis [5,6] and to track
its changes after the application of anti-atherosclerotic
therapies [7-9]. Nowadays DCE-CMR is used as a novel
endpoint in pre-clinical and clinical trials testing the effi-
cacy of anti-atherosclerotic drugs [10,11].
DCE-CMR of atherosclerosis currently suffers from in-
herent limitations. Reliable estimation of plaque perfu-
sion indices with DCE-CMR requires accurate sampling
of both the blood plasma (arterial input function, AIF)
and vessel wall (VW) enhancement curves [12,13]. Ac-
curate AIF sampling requires acquiring data with high
temporal resolution, which is very challenging when
simultaneously imaging tissues that require high spatial
resolution, such as atherosclerotic plaques [5,6,14]. To
maintain acceptable spatial and temporal resolution, few
axial slices are usually imaged, therefore sacrificing
coverage along a vascular bed [5,6]. Moreover, AIF and
VW enhancements reach very different peak contrast
agent concentrations which makes it difficult to optimize
imaging parameters [15] for both compartments in the
same acquisition. These limitations may result in inad-
equate characterization of plaque neovessels and may
impact the significance of DCE-CMR findings.
Recent studies have shown by numerical simulations
that if the AIF is acquired with a substantially higher
temporal resolution (≈1 s) than is necessary for the tis-
sue response, then the accuracy of perfusion parameters
is higher than if both curves were sampled at the same
slower temporal resolution [16,17]. Many k-spacesharing techniques, such as TRICKS [18-20], CURE [21],
keyhole [22-24], and other segmented radial [25,26]- or
spiral [27]-trajectory strategies, which are densely sam-
pled at the center of k-space, allow for increased tem-
poral resolution in a low-spatial resolution AIF image
while still acquiring time-course tissue data at higher
spatial resolutions. However, these approaches still do
not address the fact that AIF and tissue response need
to be acquired with different dynamic signal range.
Dual bolus [28-35] and dual imaging techniques
[15,36-40] can address this additional need for different
dynamic signal range for AIF and VW. Dual bolus tech-
niques allow acquiring AIF and VW images with differ-
ent spatial and temporal resolutions, spatial locations
and volumetric coverage. They provide different dy-
namic signal range for AIF and tissue by using two injec-
tions of contrast media: the first low dose injection is
used for AIF acquisition, while the second full dose in-
jection is used to acquire the tissue enhancement curves.
However, to achieve good correspondence, either the
two injections have to be matched in terms of volumes
and injection rates [41], or appropriate steps have to be
followed while processing the data [42]. Both approaches
are either not practical in a clinical setting, or render
data analysis more complicated, with a higher degree of
uncertainty.
Differently from dual-bolus, dual-imaging techniques
can acquire AIF and VW data with different imaging pa-
rameters simultaneously, in the same scan, after only
one injection of the full dose required for imaging up-
take in the target tissue, such as the vessel wall
[5,15,36-38,40]. This eliminates the need for dilution and
matching of volume and rate of separate injections and
allows measuring the AIF during uptake in the tissue of
interest. In addition, since it requires only a single injec-
tion, this approach is ideal for ease of workflow in a clin-
ical setting. However, in our knowledge the currently
available dual imaging approaches do not allow acquiring
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spatial location and volumetric coverage. This would be
particularly useful for tissues requiring imaging with high
spatial resolution, such as atherosclerotic plaques.
Here we describe a novel dual-imaging method to
address the described limitations of DCE-CMR of
atherosclerosis. We name the new sequence SHILO
(Simultaneous HI-/LOw-Temporal (Low-/Hi-Spatial) Reso-
lution DCE-imaging). Being a dual imaging approach,
both AIF and VW images can be acquired with their
optimal dynamic signal range. Differently from previ-
ous dual imaging approaches this new sequence allows
the acquisition of high temporal/low spatial resolution
AIF images and low temporal/high spatial resolution
tissue images with different temporal and spatial reso-
lution, imaging parameters and slice location. The high
temporal/low spatial resolution AIF images allow sam-
pling the time course of the contrast agent concentra-
tion in the blood plasma at a sufficient rate. The low
temporal/high spatial resolution tissue images allow
sampling the slower uptake in the vessel wall with suffi-
cient spatial resolution to capture plaques heterogeneity.
Since these features are implemented in a dual-imaging
approach, optimal AIF and VW curves can be obtained
using only one injection of contrast agent, which is most
practical in a clinical setting.
In the first part of this manuscript we present a de-
scription of the new SHILO sequence. Secondly, we per-
form numerical simulations to demonstrate that our
chosen temporal sampling strategy (high temporal/low
spatial resolution AIF interleaved with low temporal/
high spatial resolution VW images) allows more accurate
estimates of plaque perfusion, with respect to sampling
both tissues at the same, slower rate. Thirdly, we present
phantom and in vivo validation experiments, toFigure 1 Schematic representation of the SHILO segmentation/interle
spatial resolution image is acquired in 4 segments, thus leading to the acq
resolution image. L1-4, single shot AIF images. A-D, segments of the multi-
from the combination of segments A-D. Low spatial resolution images L1-4
acquired in independent location H. The black bar represents the saturatio
resolution segment.demonstrate equivalency of the SHILO MR signal to the
original 2D spoiled gradient recalled echo (SPGR) acqui-
sition and its adequacy in sampling the AIF and tissue
signals. Finally, we show feasibility of acquiring and ana-




The SHILO sequence is based on a segmented, 2D, T1-
weighted radio frequency (RF) spoiled gradient recalled
echo (SPGR), turbo field echo (TFE) acquisition. The
SHILO segmentation/interleaving scheme is shown in
Figure 1. To allow for different time resolution between
AIF and tissue acquisitions, the AIF is acquired as a
single shot low spatial/high temporal resolution image
(Figure 1, L1-4) while the tissue is simultaneously ac-
quired as a high spatial/low temporal resolution multi-
shot image (Figure 1, H1A-D). Therefore complete AIF
frames are interleaved with tissue image segments.
Spreading the acquisition of the tissue image over n seg-
ments, allows the time resolution of the single shot AIF
image to be (n + 1)/2 times faster than if the tissue image
was also acquired as single-shot, as in previously pro-
posed dual-imaging schemes [15,37]. SHILO imaging pa-
rameters can be found in Table 1. Acquisition time for
one segment is 0.8 s (TR × TFE factor). One AIF image
is acquired every 1.6 sec, while one complete tissue
image is acquired every 6.4 sec. AIF and tissue slices can
be placed independently, and were typically separated by
15–20 mm in this case. A non-selective saturation pulse
is played before every single-shot AIF acquisition
(Figure 1, black bar). Similar to Kim et. al [15], to allow
for different image contrast and dynamic signal range
between AIF and tissue acquisition, a short saturationaving scheme. The diagram illustrates an example where the high
uisition of 4 single shot AIF images for each segmented high
shot tissue image. H1: multi-shot high spatial resolution image coming
are acquired in location L, and high spatial resolution image H1 is
n pulse preceding the low spatial resolution AIF image and high spatial
Table 1 SHILO imaging parameters
Imaging parameters AIF VW
Field of view (FOV) 160 mm× 160 mm
In-plane spatial resolution 0.5 mm × 2 mm 0.5 mm× 0.5 mm
N of slices 1
Slice Thickness 3 mm
Acquisition matrix 320 × 80 320 × 320
N of acquisition segments 1 4
Turbo field echo (TFE) factor 80
Repetition time (TR) 10 ms
Echo time (TE) 4 ms
Saturation delay None 800 ms
Flip angle 15 25
K-space linear centric
Time resolution 1.6 s 6.4 s
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creased sensitivity to the high concentration in the vessel
lumen, while a longer delay, τ = 0.8 s, was used for tissue
acquisition to allow for increased signal recovery before
imaging. A repetition time (TR) of 10 ms was chosen to
trade-off increased temporal resolution at lower TR with
decreased signal saturation of longer T1 signal in the
vessel wall at longer TR. Linear k-space reordering and a
low flip angle of 15° was used for the AIF acquisition,
similarly to Gatehouse et al. [37]. For the tissue acquisi-
tion, centric reordering was chosen so that contrast de-
pends on recovery since the preceding saturation pulse
rather than SPGR contrast. A higher flip angle of 25°
was chosen to increase the signal excited at the center of
k-space from the prepared magnetization.
Dual imaging with SHILO: temporal sampling simulations
Here we show that accuracy and precision of kinetic pa-
rameters related to atherosclerotic plaque microvasculari-
zation can be improved by sampling the AIF at faster time
resolution than the plaque enhancement. This feature is
implemented in the novel SHILO sequence by interleaving
the low spatial/high temporal resolution AIF images with
high spatial/low temporal resolution tissue acquisitions. A
model AIF [43] with time resolution 0.1 s over a 5 minutes
interval was used to compute tissue uptake curves using a
modified Tofts-Kermode [44] model and a range of kinetic
parameters, representative of vessel wall perfusion indices
reported in the literature [45,46]. Kinetic parameters used
in the simulation were vp, the fraction of intra-vascular
volume; Ktrans, expressing the inflow of contrast agent
from the plasma to the tissue compartment; ve, the frac-
tion of extra-vascular extra-cellular space. The parameter
Kep expressing the backflow of contrast agent from the tis-
sue to the plasma compartment was calculated as Ktrans/ve.
150 different combination of kinetic parameters wereused, with vp values 0.001, 0.005, 0.02, 0.05, 0.1, K
trans
values 0.02, 0.06, 0.1, 0.15, 0.2 min-1, and ve values 0.1, 0.2,
0.3, 0.4, 0.6, 0.8. Two different sampling schemes were
then implemented while fitting for kinetic parameters
[16]: 1) sampling of both AIF and tissue curves at the
same increasingly lower rate (referred to as “same time
resolution”, STR) to emulate deriving the AIF curve from
the same tissue frames 2) sampling of the tissue curves
only (referred to as “different time resolution”, DTR) at an
increasingly lower rate to emulate the SHILO dual im-
aging or other dual bolus techniques. These different
levels of under-sampling simulate situations in which an
increasing number of tissue slices is acquired using both
sampling schemes. In the STR scheme both AIF and tissue
curves were under-sampled at rates 1.6, 3.2, 6.4, 12.8, 25.6
and 51.2 s (corresponding to multiples from 1 to 32 of the
AIF time resolution in SHILO). In the DTR scheme, tissue
curves were under-sampled at the same rate used for the
STR case. As for AIF, two DTR schemes were investigated
with the AIF sampled at 1.6 s and 0.8 s. The first case
(1.6 s AIF sampling) corresponds to the temporal reso-
lution of the AIF in the proposed SHILO acquisition. The
second case correspond to a hypothetical test bolus acqui-
sition, where the time resolution of the AIF is equal to the
acquisition time of one single shot image as mentioned in
the above description of the SHILO sequence, without
interleaving the acquisition of segments of tissue slices.
Comparing both these DTR schemes allows assessing the
impact on kinetic parameters estimation of interleaving
AIF and tissue acquisitions, such as is proposed in the
SHILO sequence, as opposed to the corresponding test-
bolus acquisition. For each parameter set and sampling
scheme, the simulation was repeated 6 times, each time
shifting the sampling grid by one sixth of the sampling
interval to account for a variable temporal registration of
the image sampling and bolus passage. Finally, kinetic pa-
rameters were estimated with the same modified Tofts-
Kermode model used to simulate tissue curves [44], using
non linear least squares fitting routines implemented in
Matlab (MathWorks, Natick, MA). The average and
standard deviation of estimated kinetic parameters across
the 6 variable temporal registration cases were recorded.
Relative errors, normalized by the true parameter value
were recorded and the magnitude taken. The median of
relative magnitude errors and standard deviation over the
span of kinetic parameters simulated was plotted as a
function of tissue slice temporal sampling resolution.
Validation of SHILO imaging sequence: phantom
experiments
The equivalency of the MR signal of the newly devel-
oped SHILO sequence with its low and high spatial
resolution standard SPGR counterparts was investiga-
ted using phantom experiments. Ten vials containing
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tions between 0 to 5 mM were imaged using the SHILO
acquisition and using standard saturation-prepared
2D-SPGR acquisitions equivalent to the single-shot low-
resolution and 4-fold segmented high-resolution SHILO
images. For the high resolution SPGR image a saturation
delay of 0.8 s was used as in the SHILO acquisition.
SHILO imaging parameters were the same as described
above (Table 1). An additional proton-density-weighted
image (PD-w) was acquired with the same imaging pa-
rameters described in Table 1 except TR/TE 300/2.3 ms
and flip angle = 4° to normalize the signal. Regions-of
-interest were drawn in each vial using custom made
Matlab software (MathWorks, Natick, MA). Normalized
signal from SHILO and SPGR images were plotted
against each other and compared using Pearson’s correl-
ation coefficient.
Validation of SHILO imaging sequence: in-vivo imaging
In this experiment we verified that the AIF signal mea-
sured by the SHILO sequence was comparable to the
AIF measured with an equivalent standard SPGR se-
quence in vivo. With approval from the Mount Sinai
Institutional Review Board (IRB) and after written in-
formed consent, four patients with either risk factors or
history of atherosclerosis were recruited for carotid
imaging with SHILO. Subjects were imaged on a 3T
whole body scanner (Philips Achieva) using a dedicated
8-channel array for carotid imaging. After anatomical
fast gradient echo and time-of-flight (TOF) angiographic
scout images, standard T1, T2 and PD weighted turbo
spin echo (TSE) black blood images were acquired for
characterization of the vessel wall of both common ca-
rotid arteries using imaging parameters described in pre-
vious studies [47]. For normalization of the SHILO MR
signal, an rf-spoiled 2D-SPGR image was acquired with
TR/TE 300/2.3 ms and flip angle = 4° to give proton-
density image weighting (PD-w) independent of T1 and
T2 in each of the locations of the AIF and tissue uptake
slices. AIF and tissue slices for SHILO DCE-CMR were
then positioned in the common carotid arteries, perpen-
dicular to the vessels. The tissue slice was positioned in
the location with greatest vessel wall thickness as identi-
fied on multi-slice black blood TSE scans. The AIF slice
was positioned 15–20 mm caudally with respect to the
tissue slice. To confirm in vivo equivalency between the
SHILO MR signal and the corresponding standard SPGR
acquisition, subjects were injected twice, with a low dose
of contrast agent, in the same imaging session. This
approach allows minimizing the possible confounding
effects of inter-scan variability. After placing an 18-
gauge catheter in an antecubital vein, 0.01 mmol/kg of
Gd-DTPA (Magnevist) was injected both times at a rate
of 4 ml/s, followed by 20 ml saline flush (Figure 2).Contrast agent injection started after the acquisition of 3
high spatial resolution tissue images of the SHILO- DCE
sequence (approximately 19.2 sec). During the first low
dose injection, subjects were imaged using a low reso-
lution SPGR sequence, equivalent to the AIF SHILO im-
ages. During the second low dose injection subjects were
imaged using SHILO. Following acquisition, images were
transferred to a workstation for image analysis. After
image registration and de-noising [48] image signals
were normalized by the PD-w images. One ROI was
drawn in the vessel lumen of each common carotid for
both the low resolution SHILO and SPGR AIF images.
The average ROI signal intensity versus time was
converted to T1 by using the SPGR signal equation, and
converted to concentration of gadolinium in the blood
[Gd]blood using [Eq. 1]. Contrast agent relaxivity was as-
sumed to be r = 4.2 s-1mM-1. The initial value of T1,0
was taken from the average of pre-contrast images be-
fore the influx of contrast agent. For kinetic analysis, the











Correspondence between AIF curves derived from
SHILO and standard SPGR acquisitions was evaluated
by visual inspection. AIF curves from all vessels of each
subject were averaged after appropriate translation in
time to overlay the initial bolus arrival. The Pearson’s
correlation coefficient for this set of data points was
found.
Feasibility of SHILO imaging for carotid atherosclerosis
In the same cohort of patients, and in the same imaging
session, after two low dose injections for in vivo valid-
ation of SHILO, an additional higher dose injection was
used to assess feasibility of using SHILO for perfusion
studies in carotid atherosclerosis (Figure 2). For this pur-
pose, 0.05 mmol/kg of Gd-DTPA (Magnevist) was
injected at a rate of 4 ml/s, followed by 20 ml saline
flush. In this case also, contrast agent injection started
after the acquisition of 3 high spatial resolution tissue
images of the SHILO- DCE sequence (approximately
19.2 sec). Following acquisition, images were transferred
to a workstation for image analysis. After image registra-
tion and de-noising [48] image signals were normalized
by the PD-w images. One ROI was drawn in the vessel
lumen of each common carotid for the low resolution
AIF image, while for the high resolution tissue image
ROIs encompassed the whole visible vessel wall of both
common carotids and areas in the sternocleidomastoid
muscle. The average ROI signal intensity versus time for
both AIF and tissues was converted to T1 by using the
SPGR signal equation, and converted to concentration
Figure 2 Flow chart of in vivo CMR experiment. After anatomical black blood imaging a low dose (0.01 mmol/Kg) 2D SPGR and a low dose
(0.01 mmol/Kg) SHILO scans are acquired for in vivo validation of the SHILO MR signal. Following, a higher dose (0.05 mmol/Kg) SHILO acquisition
was used to calculate perfusion parameters in the carotid vessel wall and sternocleidomastoid skeletal muscle.
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be 4.2 s-1mM-1. The initial value of T1,0 was taken from
the average of pre-contrast images before the influx of
contrast agent. AIF concentration curves were corrected
for hematocrit before kinetic modeling. A modified Tofts
model [44] was used to analyze concentration curves, by
using the AIF and tissue data from SHILO images. Kin-
etic parameters vp (fraction of vascular space), K
trans
(wash-in constant from plasma to tissue compartment),
ve (fraction of extravascular extracellular space), and Kep
(Ktrans/ve wash-out constant from tissue to plasma com-
partment) were calculated using standard non-linear
least squares fitting procedures [49] written in Matlab.
Results
Kinetic modeling simulations
Figure 3 shows the effect of under-sampling at different
rates for the AIF curve (Figure 3, panel A) and three dif-
ferent tissue curves (Figure 3, panels B-D). Red solidFigure 3 Effect of under-sampling on simulated AIF (panel A) and thr
represent different degrees of under-sampling, corresponding to decreasin
detailed in the legend. Kinetic parameters used are specified in the legendlines represent the fully sampled data, while green and
blue lines represent under-sampled data (8 and 32 times
respectively). The plot demonstrates the dramatic effect
of under-sampling on the amplitude of the AIF peak, as
well as on the initial portion of fast enhancing curves
(Figure 3, panels C and D). The effect of under-sampling
on slower enhancing curves (Figure 3, panel B) is less
evident. Results of the simulations are shown in Figures 4
and 5 for estimations of each of the kinetic parameters
separately. Figure 4 shows the median of relative magni-
tude errors, while Figure 5 shows the median standard
deviation over the span of kinetic parameters, plotted as
a function of tissue curves sampling resolution. Errors
and standard deviations for both DTR and STR schemes
increase as the tissue temporal resolution is decreased,
thus confirming the results of previous studies [16,17].
The log scale for relative error and standard deviation
shows that DTR schemes vastly outperform the
STR scheme, especially at lower temporal resolutionee simulated tissue curves (panels B to D). Different color curves
g time resolutions for an increasing number of imaged tissue slices, as
s.
Figure 4 Results of numerical simulations for percentage error. Panel A, vp. Panel B, K
trans. Panel C, ve. Panel D, Kep. Red dashed line, results
for the same time resolution (STR) sampling scheme. Green solid line, results for the different time resolution (DTR) sampling scheme
implemented in SHILO (AIF time resolution 1.6 s). Blue dash dotted line, results for the second different time resolution (DTR) sampling scheme
with AIF time resolution 0.8 s.
Figure 5 Results of numerical simulations for percentage standard deviation. Panel A, vp. Panel B, K
trans. Panel C, ve. Panel D, Kep. Red
dashed line, results for the same time resolution (STR) sampling scheme. Green solid line, results for the different time resolution (DTR) sampling
scheme implemented in SHILO (AIF time resolution 1.6 s). Blue dash dotted line, results for the second different time resolution (DTR) sampling
scheme with AIF time resolution 0.8 s.
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the two DTR schemes with AIF temporal resolutions of
0.8 sec and 1.6 sec. This indicates that the penalty paid
when interleaving AIF and tissue images in the SHILO
sequence does not substantially affect the estimation of
kinetic parameters with respect to the corresponding
dual bolus acquisition. The accuracy and precision of kin-
etic parameter estimation with the DTR schemes was bet-
ter than 1%. The median error, over the span of kinetic
parameter sets simulated, for all tissue sampling rates was
less than 1% (Figure 4). Similarly, the median standard de-
viation of the kinetic parameter estimation was less than
1% (Figure 5). Conversely, accuracy and precision of par-
ameter estimation with the STR scheme was typically be-
tween 1% and 100%, as shown by the median errors and
standard deviations shown in Figures 4 and 5.
Validation of SHILO imaging sequence: phantom
experiments
There is a close correspondence between SHILO and
standard techniques for each of the comparisons: i) low-
resolution SHILO (SHILO-LO) versus single-shot SPGR,
and ii) high resolution SHILO (SHILO-HI) versus seg-
mented SPGR with a 0.8 s saturation delay (Figure 6).
Measured signal from SHILO is plotted against those from
SPGR in Figure 6 and shows a correlation with R2 = 0.99.
This indicates that the modifications required for interleav-
ing AIF and tissue scans do not compromise the fidelity of
signal acquisition required for accurate T1 measurements
in the SHILO DCE scan.Figure 6 Correlation of normalized signal values from SHILO
and equivalent SPGR acquisitions in a phantom with a range of
T1 values corresponding to gadolinium concentrations
between 0 and 5 mM. Correlation coefficient R2 = 0.99.Validation of SHILO imaging sequence: in vivo
experiments
There is a striking correspondence between the AIF
shapes acquired with the SHILO sequence and the
standard SPGR equivalent. Shown in Figure 7 are the
AIF curves from SHILO and SPGR plotted on the same
axes for (A) the average of all AIFs from all vessels in all
subjects, and (B) for one single vessel. The correlation
coefficient between the averages AIFs for SHILO and
SPGR was R2 = 0.95 (slope 0.95, intercept - 0.01).
In-vivo imaging of carotid atherosclerosis
For a representative subject, AIF and tissue images taken
from the SHILO sequence are shown in Figure 8A and B
and indicate the image quality obtainable. Concentration-
time curves for the AIF, vessel wall, and muscle measured
from ROIs placed on the dynamic series of these images
are plotted in Figure 8C. The AIF curve clearly shows the
passage of the contrast agent bolus [43], and the tissue
curves are consistent with shapes expected for low perfu-
sion tissue [5,6,19,50-52]. Average kinetic parameter
values for the vessel wall were respectively: Ktrans : 0.27 ±
0.26 min-1; vp: : 0.02 ± 0.03; ve: 0.53 ± 0.26 . Average kinetic
parameters values for the skeletal muscle were respect-
ively: Ktrans : 0.09 ± 0.04; min
-1 vp: : 0.00 ± 0.00; ve: 0.27 ±
0.06. These values compare favorably with similar esti-
mates found in the literature [6,51-53].
Discussion
Abundant and permeable adventitial microvessels and
intra-plaque neovascularization are considered histo-
logical hallmarks of plaque vulnerability [45,54] and
therefore an attractive target for non-invasive imaging
methods aimed at identifying individuals at high-risk for
acute cardiovascular events [55,56]. DCE-MRI is a non-
invasive technique used to quantify tissues’ perfusion in
several organs [4], which has been applied in recent
years to quantify perfusion in atherosclerotic plaques
[5-8,50-52,57].
Accurate quantification of plaque perfusion is particu-
larly challenging, because of the high in-plane spatial
resolution and slice coverage required to capture the
heterogeneity of highly complex plaques. Despite the ini-
tial encouraging results [5-9,48,50-52,57], current vascu-
lar DCE-CMR protocols used to assess plaque perfusion
have failed to meet these requirements.
In this manuscript we propose a novel dual imaging
technique for improved quantification of perfusion
parameters for DCE-CMR of atherosclerosis. We name
the new sequence SHILO (Simultaneous HI-/LOw-tem-
poral (low-/hi-spatial) resolution DCE-imaging). The
new SHILO sequence proposes to overcome challenges
presented by the need to acquire both accurate AIF and
tissue DCE curves simultaneously when high-spatial
Figure 7 AIF concentration-time curves measured using SHILO and an equivalent SPGR acquisition. Panel A shows the average AIF for all
vessels in all subjects. Panel B shows the AIF from one vessel in one subject. Panel C shows the correlation between the in vivo average SPGR
and SHILO signals (R2 = 0.95; slope 0.95, intercept - 0.01).
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quisition, such as is the case of atherosclerotic plaques.
In this respect, the SHILO technique has several ad-
vantages over other dual imaging DCE techniques. The
segmented nature of the tissue acquisition allows acquir-
ing the tissue scan with higher spatial resolution than
the AIF scan, while still maintaining a high temporal
resolution on the order of 1 s for the AIF curve. In par-
ticular, segmentation allows simultaneous measurement
of the AIF and the tissue response, allowing accurate
sampling of the initial phases of both the plasma and tis-
sue uptake curve (Figure 1).
Importantly, the AIF and tissue scans can be acquired
with different dynamic signal ranges, accounting for theFigure 8 Anatomical images of a representative subject, one axial slic
(bottom left of all panels). Panel A, SHILO low spatial/high temporal reso
blood SI curve. Panel B, SHILO high spatial/low temporal resolution image
muscle (green) and vessel wall (blue) SI curves are depicted. Panel C: red li
vessel wall SI curve from high spatial/low temporal resolution SHILO; green
SHILO. Blue and green lines represent kinetic modeling fittings. X axis, time
muscle curves are plotted 25 times their measured concentrations for claritexpected differences in contrast agent concentration in
the lumen and tissue. Additionally, the separation of im-
aging segments makes the acquisition flexible, since im-
aging parameters can be manipulated to change signal
contrast properties of either scan.
Finally, the AIF image can be acquired in a separate
location from the main tissue scan as demonstrated
here. This concept can furthermore be extended to
multi-slice imaging of the tissue, while retaining a single
slice for the AIF. This will allow adequate spatial reso-
lution and slice coverage to capture the complexity of
atherosclerotic plaques, while improving estimation of
kinetic parameters because of more accurate AIF sam-
pling and will be addressed in future work.e and zoomed in insert on the right common carotid artery
lution image for AIF acquisition. Red star in insert, ROI used to sample
for tissue data acquisition. In the insert, the ROIs used to sample the
ne, AIF from low spatial/high temporal resolution SHILO; blue dots,
dots, muscle SI curve from high spatial/low temporal resolution
(min). Y axis, contrast agent concentration (mmol/l). Vessel wall and
y in the plot.
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aging approach that is the basis of our proposed new ac-
quisition sequence. Through numerical simulations, we
quantify the errors that are likely to arise from DCE
measurements if both AIF and VW wall enhancements
are sampled at the same, slow, time resolution (STR
sampling scheme). On the contrary, we demonstrate the
efficacy of our proposed sampling scheme, in which the
AIF is sampled with faster time resolution than the tis-
sue (DTR sampling scheme). Relative errors and stand-
ard deviations for the DTR scheme were vastly lower
than for the STR scheme, especially at lower temporal
resolution (Figures 4 and 5). Also evident was the close
similarity of the two DTR schemes with AIF temporal
resolutions of 0.8 sec and 1.6 sec. This indicates that
there is minimal penalty due to reducing the temporal
resolution of the AIF to accommodate the tissue image
segment in the interleaved SHILO DTR scheme. The
median accuracy and precision of kinetic parameter esti-
mation for the DTR schemes was found to be less than
1% while for STR sampling the accuracy and precision
was between 1% and 100%. This may have significant im-
pact on the estimation of plaque perfusion, since the indi-
ces vp and K
trans have been previously shown to correlate
with plaque neovascularization and several systemic risk
factors in patients with carotid atherosclerosis [6,51].
The results of our numerical simulations are in con-
cordance with similar studies presented by other groups
in the field of perfusion imaging, which shows the ro-
bustness of this approach [16,17].
Following, we show equivalency of the SHILO MR sig-
nal to the signal of corresponding low and high reso-
lution standard SPGR sequences (Figures 6 and 7). We
demonstrate with both in vitro and in vivo experiments
that the modifications applied to the native SPGR se-
quence to implement the SHILO sampling scheme, do
not affect the properties of the SPGR MR signal. This is
important when dealing with quantitative MR imaging
techniques, such as DCE-CMR, where the signal has to
be appropriately converted to concentration to extract
meaningful quantitative information.
Finally, we show feasibility of using SHILO for DCE-
CMR of subjects with carotid atherosclerosis (Figure 8).
We demonstrate ability to extract meaningful kinetic pa-
rameters from SHILO acquisitions, in the same range of
published literature values for both vessel wall and skel-
etal muscle, used as a reference tissue. In these early ex-
periments we are encouraged by the comparison of
kinetic parameters to those already in the literature. Ra-
ther than measuring substantially different kinetic pa-
rameters, we anticipate the benefit of SHILO to be in
improved precision of kinetic parameter estimates that
will improve the sensitivity of DCE measurements to
neovascularization in the tissue. This will be investigatedin further studies including correlation between DCE
measurements and histological evaluation.
Study limitations
This feasibility study presents several limitations. As
shown by numerical simulations, some advantages of the
DTR sampling scheme implemented in the SHILO se-
quence can be mostly appreciated when the disparity be-
tween the AIF and tissue time resolution is significant.
This is the case when imaging more than one tissue
slice, simultaneously with one AIF slice. In this feasibility
study we omitted extensive exploration of comparison
with acquisitions of multiple tissue slices, instead dem-
onstrating the technique with a single tissue slice. Our
aim was to demonstrate the feasibility of applying the
DTR sampling scheme, while providing physical separ-
ation between AIF and tissue slices and independence of
imaging parameters, attributes not available in other k-
space sharing techniques. Comparison of tissue curves
between SHILO and SPGR in the low dose scans was
not possible, because of the too low uptake of contrast
agent in the vessel wall. Addition of a second high-dose
to make such a comparison would have increased total
patient dose beyond the recommended guidelines. Fi-
nally, the small number of patients included and the lack
of histological samples limits the extent of the assess-
ment of the SHILO technique. However, we feel that the
data presented in this feasibility study will warrant the
future investigation of this novel approach in a more ex-
tensive study, where the absolute accuracy of plaque per-
fusion parameters will be compared against histological
features as gold standard.
Conclusions
In conclusion, the successful demonstration, in vivo, of
the new SHILO dual-imaging technique for simultan-
eous AIF and tissue-curve imaging in DCE-CMR of
atherosclerosis is promising, and warrants further inves-
tigation in wider studies measuring kinetic parameters of
atherosclerotic plaque neovascularization.
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